SCLC is sensitive to THZ1, a covalent CDK7 inhibitor with single-agent activity in T-cell acute lymphoblastic leukemia, MYCN- dependent neuroblastoma, and triple-negative breast cancer137,138. This evidence concerns the gene MYCN and neuroblastoma.